Prevalence and genotypic relatedness of carbapenem resistance among multidrug-resistant P. aeruginosa in tertiary hospitals across Thailand

Annals of Clinical Microbiology and Antimicrobials

Volumn 11, Issue , 2012, Pages

  Khuntayaporn, Piyatip ^a   Montakantikul, Preecha ^a   Mootsikapun, Piroon ^b   Thamlikitkul, Visanu ^c   Chomnawang, Mullika T ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Antimicrobial susceptibility; Carbapenem resistance; Epidemiology; Multidrug resistance; Pseudomonas aeruginosa; Pulsed field gel electrophoresis

Indexed keywords

CARBAPENEM; MEROPENEM;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; DNA FINGERPRINTING; GENOTYPE; MOLECULAR CLONING; PREVALENCE; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS; TERTIARY HEALTH CARE; THAILAND;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; PREVALENCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TERTIARY CARE CENTERS; THAILAND;

EID: 84866141743     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-11-25     Document Type: Article

References (34)

1. Mohammadtaheri Z, Pourpaki M, Mohammadi F, Namdar R, Masjedi MR. Surveillance of antimicrobial susceptibility among bacterial isolates from intensive care unit patients of a tertiary-care university hospital in Iran: 2006-2009. Chemotherapy 2010, 56(6):478-484. 10.1159/000321032, 21099220.
2. Isturiz RE, Carbon C. Antibiotic use in developing countries. Infect Control Hosp Epidemiol 2000, 21(6):394-397. 10.1086/501780, 10879571.
3. Rattanaumpawan P, Sutha P, Thamlikitkul V. Effectiveness of drug use evaluation and antibiotic authorization on patients' clinical outcomes, antibiotic consumption, and antibiotic expenditures. Am J Infect Control 2010, 38(1):38-43. 10.1016/j.ajic.2009.04.288, 19699014.
4. Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 2004, 48(12):4606-4610. 10.1128/AAC.48.12.4606-4610.2004, 529178, 15561832.
5. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005, 41(6):848-854. 10.1086/432803, 16107985.
6. Rosenthal VD, Maki DG, Jamulitrat S, Medeiros EA, Todi SK, Gomez DY, Leblebicioglu H, Abu Khader I, Miranda Novales MG, Berba R, et al. International nosocomial infection control consortium (INICC) report, data summary for 2003-2008, issued June 2009. Am J Infect Control 2010, 38(2):95-104. e102, 10.1016/j.ajic.2009.12.004, 20176284.
7. Gales AC, Sader HH, Jones RN. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in latin america: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY antimicrobial surveillance program (1997-2000). Diagn Microbiol Infect Dis 2002, 44(3):301-311. 10.1016/S0732-8893(02)00499-6, 12493178.
8. Danchaivijitr S, Judaeng T, Sripalakij S, Naksawas K, Plipat T. Prevalence of nosocomial infection in Thailand 2006. J Med Assoc Thai 2007, 90(8):1524-1529.
9. Strateva T, Yordanov D. Pseudomonas aeruginosa - a phenomenon of bacterial resistance. J Med Microbiol 2009, 58(Pt 9):1133-1148.
10. Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmeli Y. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis 1999, 28(5):1128-1133. 10.1086/514760, 10452647.
11. Giamarellos-Bourboulis EJ, Papadimitriou E, Galanakis N, Antonopoulou A, Tsaganos T, Kanellakopoulou K, Giamarellou H. Multidrug resistance to antimicrobials as a predominant factor influencing patient survival. Int J Antimicrob Agents 2006, 27(6):476-481. 10.1016/j.ijantimicag.2005.12.013, 16707252.
12. Kattan JN, Villegas MV, Quinn JP. New developments in carbapenems. Clin Microbiol Infect 2008, 14(12):1102-1111. 10.1111/j.1469-0691.2008.02101.x, 19076841.
13. Walsh TR. Clinically significant carbapenemases: an update. Curr Opin Infect Dis 2008, 21(4):367-371. 10.1097/QCO.0b013e328303670b, 18594288.
14. Masterton RG. The new treatment paradigm and the role of carbapenems. Int J Antimicrob Agents 2009, 33(2):105-110.
15. Baumgart AM, Molinari MA, Silveira AC. Prevalence of carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii in high complexity hospital. Braz J Infect Dis 2010, 14(5):433-436. 10.1590/S1413-86702010000500002, 21221469.
16. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006, 55(Pt 12):1619-1629.
17. Clinical and Laboratory Standard Institute Performance standards for antimicrobial disk susceptibility tests. Approved standard - Tenth edition, CLSI document M02-A10 2009, PA, USA: Wayne, Clinical and Laboratory Standard Institute.
18. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing 2011, PA, USA: Wayne, Twenty-first informational supplement, CLSI document M100-S21, Clinical and Laboratory Standards Institute.
19. Romling U, Wingender J, Muller H, Tummler B. A major Pseudomonas aeruginosa clone common to patients and aquatic habitats. Appl Environ Microbiol 1994, 60(6):1734-1738. 201555, 8031075.
20. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995, 33(9):2233-2239. 228385, 7494007.
21. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48(1):1-12. 10.1086/595011, 19035777.
22. Sader HS, Jones RN, Gales AC, Silva JB, Pignatari AC. SENTRY antimicrobial surveillance program report: latin american and brazilian results for 1997 through 2001. Braz J Infect Dis 2004, 8(1):25-79. 10.1590/S1413-86702004000100004, 15286878.
23. Wang J, Zhou JY, Qu TT, Shen P, Wei ZQ, Yu YS, Li LJ. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Chinese hospitals. Int J Antimicrob Agents 2010, 35(5):486-491. 10.1016/j.ijantimicag.2009.12.014, 20185276.
24. Ho J, Tambyah PA, Paterson DL. Multiresistant gram-negative infections: a global perspective. Curr Opin Infect Dis 2010, 23(6):546-553. 10.1097/QCO.0b013e32833f0d3e, 20802331.
25. Dejsirilert S, Suankratay C, Trakulsomboon S, Thongmali O, Sawanpanyalert P, Aswapokee N, Tantisiriwat W. National antimicrobial resistance surveillance, thailand (NARST) data among clinical isolates of pseudomonas aeruginosa in thailand from 2000 to 2005. J Med Assoc Thai 2009, 92(Suppl 4):S68-S75.
26. Piyakul C, Tiyawisutsri R, Boonbumrung K. Emergence of metallo-beta-lactamase IMP-14 and VIM-2 in Pseudomonas aeruginosa clinical isolates from a tertiary-level hospital in Thailand. Epidemiol Infect 2012, 140(3):539-541. 10.1017/S0950268811001294, 21733273.
27. Sekiguchi J, Asagi T, Miyoshi-Akiyama T, Kasai A, Mizuguchi Y, Araake M, Fujino T, Kikuchi H, Sasaki S, Watari H, et al. Outbreaks of multidrug-resistant Pseudomonas aeruginosa in community hospitals in Japan. J Clin Microbiol 2007, 45(3):979-989. 10.1128/JCM.01772-06, 1829129, 17122009.
28. Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect 2005, 11(12):974-984. 10.1111/j.1469-0691.2005.01271.x, 16307551.
29. Alvarez-Lerma F, Grau S, Ferrandez O. Characteristics of doripenem: a new broad-spectrum antibiotic. Drug Des Devel Ther 2009, 3:173-190. 2769234, 19920933.
30. Matthews SJ, Lancaster JW. Doripenem monohydrate, a broad-spectrum carbapenem antibiotic. Clin Ther 2009, 31(1):42-63. 10.1016/j.clinthera.2009.01.013, 19243706.
31. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004, 48(8):3086-3092. 10.1128/AAC.48.8.3086-3092.2004, 478525, 15273124.
32. Sarkar S, DeSantis ER, Kuper J. Resurgence of colistin use. Am J Health Syst Pharm 2007, 64(23):2462-2466. 10.2146/ajhp060501, 18029951.
33. Dellit TH, Owens RC, McGowan JE, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, et al. Infectious diseases society of america and the society for healthcare epidemiology of america guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007, 44(2):159-177. 10.1086/510393, 17173212.
34. Tamma PD, Cosgrove SE. Antimicrobial stewardship. Infect Dis Clin North Am 2011, 25(1):245-260. 10.1016/j.idc.2010.11.011, 21316003.